Protection against HSV-2 is added benefit of tenofovir

Protection against HSV-2 is added benefit of tenofovir

(HealthDay)—Tenofovir for HIV-1 preexposure prophylaxis (PrEP) provides the added benefit of protection against herpes simplex virus type 2 (HSV-2) acquisition, according to a study published in the July 1 issue of the Annals of Internal Medicine.

Connie Celum, M.D., M.P.H., from the University of Washington in Seattle, and colleagues conducted a study among and women in Kenya and Uganda who were seronegative for HIV-1 and HSV-2, but at high risk for HIV-1 acquisition due to having an infected partner. Participants were randomized to receive daily oral PrEP with antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF).

The researchers found that 131 participants seroconverted to HSV-2 (79 of 1,041 assigned to tenofovir or FTC-TDF PrEP [HSV-2 incidence, 5.6 per 100 person-years] versus 52 of 481 assigned to [HSV-2 incidence, 7.7 per 100 person-years]). With daily oral PrEP, the hazard ratio (HR) for HSV-2 acquisition was 0.70 (P = 0.047) compared with placebo, with an absolute risk reduction of 2.1 per 100 person-years. The HR for PrEP was 0.67 (P = 0.038) among the 1,044 participants with HSV-2-infected partners, compared to placebo, with an absolute risk reduction of 3.1 per 100 person-years.

"Modest protection against HSV-2 is an added benefit of HIV-1 prevention with oral tenofovir-based PrEP," the authors write.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Drugs used to treat HIV also reduce risk of HIV infection

Jul 10, 2012

People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers ...

Recommended for you

New study reveals why some people may be immune to HIV-1

Nov 20, 2014

Doctors have long been mystified as to why HIV-1 rapidly sickens some individuals, while in others the virus has difficulties gaining a foothold. Now, a study of genetic variation in HIV-1 and in the cells ...

Virus discovery could impact HIV drug research

Nov 20, 2014

A research team led by Portland State University (PSU) biology professor Ken Stedman has unlocked the structure of an unusual virus that lives in volcanic hot springs. The discovery could pave the way for better drugs to ...

UN warns over threat of AIDS rebound

Nov 19, 2014

South African actress Charlize Theron threw her weight Tuesday behind an urgent new UN campaign to end AIDS as a global health threat by 2030.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.